Fig. 4: Patient 2: Immunological changes and serologic responses in MAG neuropathy treated with teclistamab.

A CD3 + T-cell counts and CD19 + B-cell counts after teclistamab therapy. Green areas: Normal values. B Relative sBCMA levels showed a temporary decrease during the treatment phase whereas the M-protein remained undetectable until month 6. sBCMA measurements were performed three times at each time point. C Course of serum neurofilament (Nfl) levels showing reduction after teclistamab treatment. Green area: Normal values. D Left: Immunostaining of anti-MAG antibodies at baseline, 3 weeks and 3 months after first teclistamab dose showing decrease of MAG antibody titers already at week 3. MAG antibodies were negative at month 3. Right: Course of serum MAG antibody titers. Scale bars: 10 µm. E IgM and IgG levels after teclistamab treatment. Purple triangles indicate time points of supplementary IVIG infusion. Green area: Normal values. F Interleukin-6 (IL-6) levels and neutrophil levels after teclistamab. A second increase of IL-6 was observed during month 5 when the patient had a mild bronchitis. Green area: Normal values. Dashed lines in A and F indicate time points of teclistamab injections (0.06: 0.06 mg/kg body weight, 0.3: 0.3 mg/kg body weight; 1.5: 1.5 mg/kg body weight). Abbreviations: MAG-Ab: Anti-MAG antibodies, IVIG: intravenous immunoglobulin. Source data are provided as a Source Data file.